Journal
ACS CHEMICAL BIOLOGY
Volume 14, Issue 9, Pages 1904-1912Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acschembio.9b00367
Keywords
-
Categories
Funding
- Wellcome Trust Investigator Award [104641/Z/14/Z]
- Boehringer-Ingelheim Fonds PhD Fellowship
- Janggen-Pohn-Stiftung Award
- Swiss National Science Foundation Award
- Wellcome Trust [104641/Z/14/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
Nucleoside analogues are widely used in clinical practice as chemotherapy drugs. Arabinose nucleoside derivatives such as fludarabine are effective in the treatment of patients with acute and chronic leukemias and non-Hodgkin's lymphomas. Although nucleoside analogues are generally known to function by inhibiting DNA synthesis in rapidly proliferating cells, the identity of their in vivo targets and mechanism of action are often not known in molecular detail. Here we provide a structural basis for arabinose nucleotide-mediated inhibition of human primase, the DNA-dependent RNA polymerase responsible for initiation of DNA synthesis in DNA replication. Our data suggest ways in which the chemical structure of fludarabine could be modified to improve its specificity and affinity toward primase, possibly leading to less toxic and more effective therapeutic agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available